Non Hodgkin Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Recruiting
  • Hodgkin Lymphoma
  • +3 more
  • Biostrap arm band
  • Palo Alto, California
    Stanford University
2022-03-29
Mar 29, 2022
C
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Recruiting
  • Lymphoma, Non-Hodgkin
  • +6 more
  • CB-010
  • +2 more
  • Scottsdale, Arizona
  • +5 more
2022-04-05
Apr 5, 2022
H
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
2022-04-06
Apr 6, 2022
A
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Not yet recruiting
  • Non Hodgkin Lymphoma
  • (no location specified)
2022-03-31
Mar 31, 2022
I
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
Recruiting
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +48 more
2022-03-30
Mar 30, 2022
K
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Goshen, Indiana
  • +39 more
2022-03-28
Mar 28, 2022
A
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Active, not recruiting
  • Non Hodgkin Lymphoma
  • Tucson, Arizona
  • +32 more
2022-03-25
Mar 25, 2022
W
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
Enrolling by invitation
  • Breast Neoplasm
  • +5 more
  • AH-HA Tool in the EPIC EHR
  • Fort Smith, Arkansas
  • +7 more
2022-03-25
Mar 25, 2022
I
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
Not yet recruiting
  • Non Hodgkin Lymphoma
  • Liposomal Mitoxantrone Hydrochloride dose level 1
  • +6 more
  • (no location specified)
2022-03-17
Mar 17, 2022
U
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Withdrawn
  • Acute Lymphoblastic Leukemia
  • +2 more
  • PACE CART19
  • (no location specified)
2022-03-09
Mar 9, 2022
S
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
2022-03-23
Mar 23, 2022
T
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
2022-03-22
Mar 22, 2022
U
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
2022-03-08
Mar 8, 2022
T
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +16 more
2022-03-22
Mar 22, 2022
C
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
Suspended
  • Mediastinal Lymphoma
  • +2 more
  • Standard treatment protocol with combined chemoradiation
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital
2022-03-08
Mar 8, 2022
P
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Active, not recruiting
  • Multiple Myeloma
  • +3 more
  • Denver, Colorado
  • +4 more
2022-03-18
Mar 18, 2022
M
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Active, not recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Total Body Irradiation
  • +4 more
  • New York, New York
    Memorial Sloan - Kettering Cancer Center
2022-03-16
Mar 16, 2022
H
Duvelisib in Combination With CC-486 in Lymphoid Malignancy
Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
2022-03-14
Mar 14, 2022
C
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
Recruiting
  • Late Effects
  • +8 more
  • PASCA intervention
  • Lyon, France
    Centre Leon Berard
2022-03-15
Mar 15, 2022
I
Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers
Recruiting
  • Solid Tumor
  • +8 more
  • Duarte, California
  • +8 more
2022-03-11
Mar 11, 2022
B
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
2022-03-10
Mar 10, 2022
T
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
Recruiting
  • Non Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Nanjing, Jiangsu, China
  • +1 more
2022-03-09
Mar 9, 2022
M
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Tucson, Arizona
  • +97 more
2022-03-10
Mar 10, 2022
M
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Zandelisib (ME-401)
  • Tucson, Arizona
  • +115 more
2022-03-08
Mar 8, 2022
U
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022